Default company panoramic image
Logo

Immunity Pharma Ltd.

IPL develops drugs that activate self-healing processes in neurologic diseases. Our lead drug IPL344 has a strong case for stabilizing ALS.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Mevaseret Zion, IL
  • Currency USD
  • Founded March 2007
  • Employees 1
  • Website immunitypharma.com

Company Summary

We develop innovative drugs that stimulate therapeutic cell-signalling processes for the treatment of neuro-degenerative diseases, with an initial focus on ALS (Lou Gehrig's disease) - which has no cure, and massive market potential. Our drug bypasses cracks in the signalling processes induced by the disease conditions and has potential to succeed when many other drugs failed. We are now approaching Phase I-II clinical trial with ALS patients

Team

  • Default avatar
    Anat Eitan
    Director

    Founder and CEO of VacciGuard
    Ms. Eitan has 15 years’ experience in senior managerial functions in the drug development industry, including the R&D division at Teva Pharmaceuticals and Metabogal (now Protalix).

  • Default avatar
    Eran Ovadia
    CEO

    Eran Ovadia (MBA) is an experienced CEO with life-science education and broad management expertise in high-tech startups and corporations (Comverse), from business marketing to technology development and project delivery, the search and application of complex, out-of-the-box solutions and smart and efficient utilization of resources. For 10 years he has concentrated on bio-medical entrepreneurship, technology discovery, picking and development.

  • Default avatar
    Oren Becker
    Director

    CEO of Dynamix Pharmaceuticals
    Dr. Becker has 20 years’ management experience in drug discovery and development. He co-founded and/or held key positions in a number of pharma companies, including Predix Pharmaceuticals.

  • Default avatar
    Irun R. Cohen
    Scientific Advisory Board

    Professor Emeritus of Immunology, Weizmann Institute of Science Prof. Cohen is an expert in chronic inflammatory and degenerative diseases and in translating pre-clinical research to clinical applications. He discovered and developed a peptide that will complete multi-national Phase 3 clinical trials for type-1 diabetes in 2012. He also developed T-cell vaccination therapy for Multiple Sclerosis, which is now in Phase 2 clinical trials in the US.

  • Default avatar
    Stanley Appel
    Scientific Advisory Board

    Holds the chair for the Treatment and Research of ALS and is director of the Neurological Institute, Methodist Hospital. He is professor of neurology at Weill Medical College, Cornell University. Previously, he chaired the department of neurology at Baylor College and served as chief of the neurology division at Duke University Medical Center. He is a past director of the National Institute of Aging Alzheimer's Disease Research Center.

  • Default avatar
    Robert H. Brown
    Scientific Advisory Board

    Prof. Brown is chair of the Department of Neurology at the University of Massachusetts Medical Center and director of the Day Neuromuscular Research Laboratory at the University of Massachusetts Medical School. His lab has focused on the identification of gene defects that elucidate the molecular pathogenesis of selected neuromuscular diseases, including ALS.

Advisors

  • Default avatar
    Lawyers Kantor & Co. - Ronen Kantor
    Lawyer
    Unconfirmed
    Default avatar
    Ernst & Young - Kost, Forer, Gabbay & Kasierer
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Landes Bioscience, Texas USA
    Unconfirmed
    Default avatar
    Yoav Chelouche (Managing Partner Aviv Venture Capital)
    Unconfirmed
    Default avatar
    Ailon Michaeli (past CFO at Housing & Construction Ltd , Comverse Network Systems)
    Unconfirmed